Free delivery over $3201–3 day express deliveryDispatched Australia-wideIndependent lab reports published
Free bac water with any 2 vials · no code · ends Thu 26 NovBlack Fridayopens Fri 27 Nov ·  
Shop now

CJC-1295 no DAC – 10mg

$100.00

CJC-1295 No DAC 10mg is an experimental GHRH-related peptide commonly associated with Modified GRF(1–29) and investigated in GHRH receptor signalling, pituitary endocrine physiology and peptide structure–activity research.

Available from Peps Aussie Australia for controlled laboratory research and analytical applications.

  • Product: CJC-1295 No DAC
  • Size: 10mg
  • Peptide Type: Synthetic GHRH-related peptide
  • Common Commercial Association: Modified GRF(1–29)
  • Primary Research Receptor: GHRH receptor (GHRHR)
  • Research Areas: GHRH receptor pharmacology, pituitary signalling and peptide chemistry
  • Molecular Identity: Exact sequence and absence of DAC require verification
  • Quality Documentation: Available Certificates of Analysis (COA)
  • Shipping: Australian dispatch, subject to stock availability
  • Intended Use: Scientific and laboratory research only

For laboratory research use only. Not intended for human or animal consumption, administration, bodybuilding or therapeutic use.

Free Delivery on all orders above $320

Out of stock

Description

CJC-1295 No DAC 10mg – GHRH Receptor Research Peptide Australia

CJC-1295 No DAC 10mg is an experimental growth-hormone-releasing hormone (GHRH) analogue listed by Peps Aussie Australia as reference material for scientific investigation, laboratory analysis and controlled experimental research.

CJC-1295 No DAC is a commercial designation commonly associated with Modified GRF(1–29), a synthetic peptide analogue based on the first 29 amino acid residues of human growth-hormone-releasing hormone.

The term No DAC indicates that the material is described as lacking the drug-affinity-complex modification associated with certain CJC-1295 preparations.

This distinction is important because DAC-containing CJC-1295 and non-DAC GHRH analogues may differ substantially in their molecular structure and pharmacokinetic characteristics.

Scientific interest in CJC-1295 No DAC centres on GHRH receptor signalling, pituitary endocrine physiology and growth hormone-associated research.

GHRH is a naturally occurring hypothalamic peptide involved in regulating growth hormone secretion through activation of the growth-hormone-releasing hormone receptor (GHRHR).

Synthetic GHRH analogues are investigated to better understand receptor interactions, peptide structure–activity relationships and endocrine signalling mechanisms.

However, the commercial designation CJC-1295 No DAC does not independently establish a unique molecular identity or guarantee equivalence to a particular published peptide preparation.

The exact amino acid sequence, molecular modifications, terminal groups and formulation must be confirmed through product-specific analytical documentation.

Peps Aussie lists CJC-1295 No DAC in a nominal 10mg size for laboratory research and analytical applications.

Important: CJC-1295 No DAC is intended strictly for laboratory research and analytical purposes. It is not supplied for human or animal consumption, injection, administration, bodybuilding, performance enhancement, therapeutic use or clinical treatment.

What Is CJC-1295 No DAC?

CJC-1295 No DAC is a commercial name commonly used for a synthetic GHRH-related peptide that lacks the drug-affinity-complex modification associated with DAC-containing CJC-1295.

It is frequently associated with Modified GRF(1–29), a modified analogue of the first 29 amino acid residues of human growth-hormone-releasing hormone.

Modified GRF(1–29) is commonly described as incorporating amino acid substitutions intended to alter peptide stability and receptor pharmacology.

However, the name CJC-1295 No DAC is not sufficiently precise to establish the supplied peptide’s molecular structure without supporting documentation.

Understanding Modified GRF(1–29)

Modified GRF(1–29) is a synthetic peptide analogue derived from the biologically active N-terminal region of human GHRH.

It is commonly described as containing 29 amino acid residues.

Certain Modified GRF(1–29) preparations incorporate substitutions at positions 2, 8, 15 and 27 relative to the corresponding human GHRH fragment.

These modifications are relevant to structure–activity relationship research.

However, the exact sequence and terminal chemistry of any commercially supplied preparation should be independently verified.

Understanding the Drug-Affinity-Complex Modification

The drug-affinity-complex modification, commonly abbreviated as DAC, is associated with certain CJC-1295 preparations designed to interact with circulating proteins.

DAC-containing CJC-1295 has been investigated for its extended pharmacokinetic characteristics.

A preparation described as No DAC should not be assumed to share the same molecular structure or duration of action.

Research findings involving DAC-containing CJC-1295 should not automatically be applied to non-DAC material.

CJC-1295 No DAC Peptide Research and Scientific Applications

Research involving GHRH analogues spans receptor pharmacology, endocrine physiology, peptide chemistry and analytical characterisation.

The following sections describe relevant scientific research topics rather than proven therapeutic effects of the Peps Aussie material.

1. GHRH Receptor Pharmacology Research

One of the primary areas associated with CJC-1295 No DAC research involves the growth-hormone-releasing hormone receptor.

GHRHR is a G protein-coupled receptor involved in regulating growth hormone secretion.

Experimental investigations involving GHRH analogues have examined receptor-mediated signalling.

Relevant research topics include:

  • GHRH receptor activation.
  • Ligand–receptor interactions.
  • Receptor-associated signalling.
  • Concentration–response relationships.
  • G protein-coupled receptor biology.
  • Experimental endocrine models.
  • Comparative peptide pharmacology.

These investigations contribute to understanding the molecular behaviour of GHRH receptor agonists.

However, receptor activity does not establish clinical safety or therapeutic efficacy.

2. Pituitary Growth Hormone Signalling Research

Growth hormone is a peptide hormone released by the anterior pituitary gland.

Its secretion is regulated through interactions between hypothalamic signalling and pituitary function.

GHRH is one of the principal physiological regulators of growth hormone secretion.

Research involving GHRH analogues has examined:

  • Pituitary endocrine physiology.
  • Growth hormone-associated signalling.
  • Hypothalamic–pituitary interactions.
  • Hormone-associated measurements.
  • Receptor-mediated responses.
  • Experimental endocrine models.

These investigations contribute to understanding growth hormone regulation.

However, findings from GHRH analogue research do not establish that independently supplied CJC-1295 No DAC produces predictable or beneficial hormonal effects in humans.

3. Intracellular Signalling Research

Activation of GHRHR is associated with intracellular signalling pathways involved in endocrine regulation.

These pathways are commonly investigated using receptor-based experimental models.

Relevant research topics include:

  • G protein-coupled receptor signalling.
  • Cyclic AMP-associated pathways.
  • Cellular second messengers.
  • Receptor activation.
  • Intracellular regulatory mechanisms.
  • Experimental signalling assays.

These investigations contribute to understanding how GHRH receptor activation influences cellular responses.

However, the specific activity of a commercially labelled CJC-1295 No DAC preparation requires verified molecular identity and direct experimental evidence.

4. Structure–Activity Relationship Research

Structure–activity relationship research examines how molecular modifications influence biological activity.

GHRH analogues are relevant to investigations involving peptide sequence modifications and receptor pharmacology.

Relevant research topics include:

  • Amino acid substitutions.
  • Peptide receptor interactions.
  • Molecular stability.
  • Enzymatic degradation.
  • Receptor affinity.
  • Comparative peptide chemistry.
  • Experimental pharmacological assays.

These investigations contribute to understanding how changes in peptide structure may influence receptor-associated activity.

However, even small molecular differences can affect biological behaviour.

5. Peptide Stability and Degradation Research

Peptide stability is an important consideration in laboratory research.

Synthetic GHRH analogues may differ in their susceptibility to enzymatic degradation and other chemical processes.

Relevant research topics include:

  • Peptide degradation.
  • Enzymatic stability.
  • Chemical stability.
  • Molecular modifications.
  • Analytical degradation products.
  • Experimental peptide handling.
  • Comparative stability assessments.

These investigations contribute to understanding the physicochemical characteristics of GHRH analogues.

However, stability findings involving one molecular form should not automatically be transferred to another.

6. GHRH and Endocrine Feedback Research

The growth hormone axis involves interactions between hypothalamic hormones, pituitary secretion and downstream endocrine signalling.

GHRH participates in this regulatory system.

Relevant research topics include:

  • Hypothalamic–pituitary signalling.
  • Growth hormone regulation.
  • Endocrine feedback mechanisms.
  • Hormone-associated biomarkers.
  • Receptor-mediated responses.
  • Experimental endocrine physiology.

These investigations provide context for understanding the role of GHRH analogues in endocrine research.

However, changes in endocrine biomarkers are not inherently beneficial and require careful interpretation.

7. CJC-1295 No DAC Compared With CJC-1295 DAC, Tesamorelin and Ipamorelin

CJC-1295 No DAC is sometimes discussed alongside other experimental peptides associated with growth hormone signalling.

However, these compounds are not chemically or pharmacologically interchangeable.

CJC-1295 No DAC:

  • A commercial designation commonly associated with Modified GRF(1–29).
  • Described as lacking the DAC modification.
  • Investigated in the context of GHRH receptor pharmacology.
  • Requires sequence verification.

CJC-1295 With DAC:

  • A distinct DAC-containing GHRH analogue.
  • Has been investigated for extended pharmacokinetic characteristics.
  • Has published clinical pharmacology research.
  • Should not be assumed equivalent to non-DAC material.

Tesamorelin:

  • A synthetic GHRH analogue.
  • Activates the GHRH receptor.
  • Has a different molecular structure.
  • Has registered pharmaceutical formulations for specific indications in certain jurisdictions.

Ipamorelin:

  • A synthetic growth hormone secretagogue peptide.
  • Primarily associated with GHSR1a receptor activation.
  • Acts through a different receptor system.
  • Is not chemically equivalent to GHRH analogues.

Research findings involving one compound should not automatically be attributed to another.

8. CJC-1295 No DAC Analytical Characterisation and Quality Research

Analytical characterisation is particularly important for research materials sold under commercial names that may be used inconsistently.

Laboratories evaluating CJC-1295 No DAC may investigate:

  • Confirmation of the declared amino acid sequence.
  • Verification of expected amino acid substitutions.
  • Confirmation of the absence of a DAC modification.
  • Molecular mass determination.
  • Terminal group characterisation.
  • Chromatographic purity profiles.
  • Related peptide impurities.
  • Quantitative content determination.
  • Stability and degradation characteristics.
  • Batch-to-batch analytical consistency.

Analytical techniques may include high-performance liquid chromatography (HPLC), mass spectrometry (MS) and other suitable methods.

A chromatographic purity result alone does not establish that a commercially supplied preparation is chemically identical to Modified GRF(1–29) or another published GHRH analogue.

CJC-1295 No DAC 10mg Research Peptide Specifications

Peps Aussie lists CJC-1295 No DAC in a nominal 10mg size.

Specification Details
Product name CJC-1295 No DAC
Listed size 10mg
Peptide type Synthetic GHRH-related peptide
Common commercial association Modified GRF(1–29)
Commonly described length 29 amino acid residues
DAC modification Described as absent; requires verification
Exact amino acid sequence Requires verification
Primary research receptor Growth-hormone-releasing hormone receptor (GHRHR)
Research category Endocrine signalling and receptor pharmacology
Research areas GHRH receptor signalling, pituitary growth hormone regulation and peptide structure–activity relationships
Supplier Peps Aussie Australia
Intended use Laboratory research and analytical investigation only

The scientific characteristics above describe the research context associated with CJC-1295 No DAC. They do not independently verify the identity, composition, purity or content of the supplied material.

Exact molecular identity, amino acid sequence, terminal modifications, salt form, formulation, physical appearance, fill quantity and excipients should be confirmed against the applicable product label and supporting lot documentation.

Important: The commercial designation CJC-1295 No DAC does not independently establish equivalence to Modified GRF(1–29), DAC-containing CJC-1295 or any particular published experimental preparation.

CJC-1295 No DAC Certificate of Analysis (COA) and Quality Documentation

Analytical verification is particularly important when evaluating research materials with potentially ambiguous commercial nomenclature.

Peps Aussie maintains a dedicated resource where researchers can review available Certificates of Analysis and supporting analytical records.

View Peps Aussie Certificates of Analysis

When evaluating CJC-1295 No DAC analytical documentation, researchers should consider:

  • Peptide identity: Whether testing supports the declared molecular identity.
  • Sequence verification: Whether the amino acid sequence has been established.
  • DAC status: Whether the absence of the DAC modification is supported.
  • Terminal modifications: Whether relevant terminal groups have been characterised.
  • Molecular mass: Whether testing supports the expected molecular characteristics.
  • Purity assessment: Whether suitable methods were used to evaluate impurities.
  • Content determination: Whether quantitative testing supports the declared 10mg quantity.
  • Batch traceability: Whether the certificate corresponds to the supplied production lot.
  • Testing methodology: Whether the analytical techniques are appropriate for the peptide.
  • Additional testing: Whether relevant contamination or other quality assessments were performed.

High-performance liquid chromatography and mass spectrometry are commonly used in peptide characterisation.

However, a general purity result does not independently establish whether the material contains the expected sequence or lacks the DAC modification.

A certificate should be interpreted according to the tests actually performed.

The availability of a certificate does not automatically establish sterility, endotoxin status, a particular purity percentage, pharmaceutical-grade manufacturing or independent verification of every production batch.

CJC-1295 No DAC Storage and Laboratory Handling

Research peptides require appropriate handling to support sample integrity and experimental reproducibility.

Storage requirements for CJC-1295 No DAC depend on its exact molecular structure, formulation, packaging and validated manufacturer stability information.

Laboratories should consider:

  • Appropriate storage temperature.
  • Protection from light and moisture where necessary.
  • Suitable laboratory containers.
  • Compatibility with analytical solvents.
  • Stability following sample preparation.
  • Potential degradation during storage.
  • Appropriate laboratory handling and disposal procedures.

No universal storage temperature or reconstitution procedure is recommended without verified product-specific documentation.

Because commercially labelled CJC-1295 preparations may differ in molecular identity, storage assumptions should not be transferred between DAC-containing and non-DAC products without supporting evidence.

All laboratory work should be performed by appropriately qualified personnel using validated procedures and suitable safety controls.

CJC-1295 No DAC 10mg Australia – Product Availability and Shipping

Peps Aussie maintains an Australian-based catalogue of research peptides and laboratory materials for scientific and analytical applications.

CJC-1295 No DAC 10mg is the currently listed nominal product size.

Pricing and ordering availability should be confirmed through the product selection area. Inventory is currently pending confirmation.

For current information regarding Australian dispatch, delivery arrangements, processing times and applicable restrictions, visit the Peps Aussie Shipping Policy.

Frequently Asked Questions About CJC-1295 No DAC

What is CJC-1295 No DAC?

CJC-1295 No DAC is a commercial designation commonly associated with a synthetic GHRH-related peptide described as lacking the drug-affinity-complex modification.

What is CJC-1295 No DAC studied for?

Laboratory research focuses on GHRH receptor signalling, pituitary growth hormone regulation and synthetic peptide pharmacology.

Is CJC-1295 No DAC the same as Modified GRF(1–29)?

The names are frequently used interchangeably in commercial settings, but they should not be assumed chemically identical without verification of the amino acid sequence and molecular modifications.

What does No DAC mean?

No DAC indicates that the peptide is described as lacking the drug-affinity-complex modification associated with certain CJC-1295 preparations.

Is CJC-1295 No DAC the same as CJC-1295 With DAC?

No. The presence or absence of the DAC modification is an important molecular distinction that may affect pharmacokinetic characteristics.

Does CJC-1295 No DAC activate the GHRH receptor?

GHRH analogues are investigated for their interaction with the GHRH receptor. However, the activity of a particular commercial preparation requires verified molecular identity and direct supporting evidence.

Does CJC-1295 No DAC increase growth hormone?

GHRH receptor activation is associated with growth hormone signalling. However, findings involving specific GHRH analogues do not establish predictable hormonal responses or clinical benefits from independently supplied CJC-1295 No DAC material.

Is CJC-1295 No DAC the same as Tesamorelin?

No. Tesamorelin is a distinct synthetic GHRH analogue with a different molecular structure and clinical research history.

Is CJC-1295 No DAC the same as Ipamorelin?

No. CJC-1295 No DAC is associated with GHRH receptor research, while Ipamorelin is a growth hormone secretagogue receptor agonist.

Is CJC-1295 No DAC approved for human use?

No therapeutic approval or clinical suitability is claimed for the Peps Aussie CJC-1295 No DAC research product.

What size does Peps Aussie list?

Peps Aussie lists CJC-1295 No DAC in a 10mg nominal size. Researchers should verify the individual vial label and supporting analytical documentation.

Does CJC-1295 No DAC have a Certificate of Analysis?

Available analytical documentation can be reviewed through the Peps Aussie Certificates of Analysis page. Researchers should confirm that any applicable certificate corresponds to the specific production lot and evaluate the tests performed.

How should CJC-1295 No DAC be stored?

Storage requirements depend on the molecular structure, formulation and validated stability characteristics. Follow the manufacturer’s product-specific documentation and established laboratory procedures.

Is CJC-1295 No DAC approved for veterinary use?

No veterinary approval or clinical suitability is claimed for the Peps Aussie research product.

It is not supplied for animal consumption, administration, diagnosis, prevention or treatment.

CJC-1295 No DAC Research Peptides at Peps Aussie Australia

Peps Aussie maintains a catalogue of laboratory research peptides and scientific materials for researchers investigating molecular biology, peptide chemistry and endocrine signalling.

CJC-1295 No DAC remains a subject of scientific interest because of its association with GHRH receptor pharmacology, pituitary growth hormone regulation and peptide structure–activity research.

Researchers evaluating CJC-1295 No DAC 10mg should prioritise accurate molecular identification, confirmation of DAC status, appropriate analytical documentation, batch traceability and validated laboratory procedures.

Explore the Peps Aussie research catalogue at pepsaussie.com.


Research Use Only Disclaimer

CJC-1295 No DAC 10mg is intended strictly for laboratory research and analytical purposes only.

This product is not intended for human or animal consumption, injection, administration, bodybuilding, performance enhancement, therapeutic use or clinical treatment.

Descriptions of published scientific research are provided for educational and informational purposes only. They do not establish muscle growth, fat loss, recovery enhancement, anti-ageing benefits, clinical safety or therapeutic suitability for the material offered.

Findings involving DAC-containing CJC-1295 or other GHRH analogues should not be assumed to apply to independently supplied CJC-1295 No DAC material without verified chemical identity and direct supporting evidence.

No dosing, self-administration or therapeutic guidance is provided.

Additional information

Size

10mg

Reviews

There are no reviews yet.

Reviews here are by invitation. We email a link once your order has arrived, so every review comes from someone who received the product. Lost the email? Find your review link.

Related Products

Search Products